Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction

Brian Godman, Ana Luísa Caires de Souza, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior

Research output: Contribution to conferenceAbstract

Abstract

The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

Conference

ConferenceII International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”
CountryUnited Kingdom
CityBelo Horizonte
Period10/11/1413/11/14

Fingerprint

Drug Utilization
Isophane Insulin
Costs and Cost Analysis
Type 1 Diabetes Mellitus
Brazil
Insulin
Safety
Growth
Insulin Glargine
Direction compound

Keywords

  • insulin glargine
  • systematic review
  • Brazil
  • law suits

Cite this

Godman, B., de Souza, A. L. C., de Assis Acurcio, F., & Guerra Júnior, A. A. (2014). Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction. Abstract from II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom.
Godman, Brian ; de Souza, Ana Luísa Caires ; de Assis Acurcio, Francisco ; Guerra Júnior, Augusto Afonso. / Insulin glargine in a Brazilian State : an assessment of drug utilization, effectiveness and value to provide future direction. Abstract from II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom.1 p.
@conference{e7f4fb504b944d5197972447a4a31194,
title = "Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction",
abstract = "The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291{\%} per year. This growth has been driven by an increasing number of successful law suits and a 536{\%} price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.",
keywords = "insulin glargine, systematic review, Brazil, law suits",
author = "Brian Godman and {de Souza}, {Ana Lu{\'i}sa Caires} and {de Assis Acurcio}, Francisco and {Guerra J{\'u}nior}, {Augusto Afonso}",
year = "2014",
language = "English",
note = "II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment” ; Conference date: 10-11-2014 Through 13-11-2014",

}

Godman, B, de Souza, ALC, de Assis Acurcio, F & Guerra Júnior, AA 2014, 'Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction' II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom, 10/11/14 - 13/11/14, .

Insulin glargine in a Brazilian State : an assessment of drug utilization, effectiveness and value to provide future direction. / Godman, Brian; de Souza, Ana Luísa Caires; de Assis Acurcio, Francisco; Guerra Júnior, Augusto Afonso.

2014. Abstract from II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - Insulin glargine in a Brazilian State

T2 - an assessment of drug utilization, effectiveness and value to provide future direction

AU - Godman, Brian

AU - de Souza, Ana Luísa Caires

AU - de Assis Acurcio, Francisco

AU - Guerra Júnior, Augusto Afonso

PY - 2014

Y1 - 2014

N2 - The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

AB - The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

KW - insulin glargine

KW - systematic review

KW - Brazil

KW - law suits

UR - http://www.farmacoeconomiasus.com.br/sobre_en.html

M3 - Abstract

ER -

Godman B, de Souza ALC, de Assis Acurcio F, Guerra Júnior AA. Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction. 2014. Abstract from II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom.